What is PLYX's health score?

Polaryx Therapeutics, Inc. (PLYX) has a TradeApes health score of 49 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is PLYX's estimated fair value?

Based on our 5-year discounted cash flow model, Polaryx Therapeutics, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is PLYX undervalued or overvalued?

Our model currently rates PLYX as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for PLYX... Refresh in a moment for the full analysis.

Polaryx Therapeutics, Inc. (PLYX)

Healthcare Inconclusive inconclusive mixed

$2.53

Updated: 2026-06-04

TradeApes Score

Financial Strength

55 Mixed

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

50 Mixed

Risk

80 Strong

Key Findings

+ Strong liquidity — current assets more than 2× current liabilities

Unlock Full Report →

− Negative ROIC — business destroying value on invested capital

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.